Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Condition

Constipation, chronic

3

Unknown

2,578

Pain

614

Cancer

592

Hypertension

567

All Match

Any Match

Exclude Selected

Exclude Selected

Development Status

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Serotonin 4 (5-HT4) receptor

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2018

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Janssen

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

3

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

3

DRUG BANK

3

EPA CompTox

3

EVMPD

3

FDA UNII

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ALIMENTARY TRACT AND METABOLISM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DRUGS FOR CONSTIPATION

1

DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

DRUGS FOR CONSTIPATION

1

DRUGS FOR FUNCTIONAL BOWEL DISORDERS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Drugs acting on serotonin receptors

1

Other drugs for constipation

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

2

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 3 of 3 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PRUCALOPRIDE

0A09IUW5TP

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 4 (5-HT4) receptor

Conditions:

Constipation, chronic

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin...

5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

PRUCALOPRIDE HYDROCHLORIDE

M8IYX9Z79V

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 4 (5-HT4) receptor

Conditions:

Constipation, chronic

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin...

5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

PRUCALOPRIDE SUCCINATE

4V2G75E1CK

Export Data
Search for Structure

Status:

US Approved Rx (2018)

First approved in 2018

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Serotonin 4 (5-HT4) receptor

Conditions:

Constipation, chronic

Prucalopride is a novel enterokinetic compound and is the first representative of the benzofuran class. Prucalopride is a potent, selective and specific serotonin 5-HT4 receptor (5-HT4-R) agonist. Prucalopride (Resolor®), a highly selective serotonin...

5-HT4 receptor agonist, is indicated in the European Economic Area for the treatment of adults with chronic idiopathic constipation (CIC) in whom laxatives have failed to provide adequate relief.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1